79064-26-9

Basic information

• Product Name: 9-benzyl-2,6-dichloro-9H-purine
• Synonyms: 9-benzyl-2,6-dichloro-9H-purine;9-benzyl-2,6-dichloropurine
• CAS NO: 79064-26-9
• Molecular Formula: C₁₂H₈Cl₂N₄
• Molecular Weight: 279.12472
• Mol File: 79064-26-9.mol
• Article Data: 27

Chemical Properties

• Melting Point: 136-138 °C
• Boiling Point: 430.5°Cat760mmHg
• Flash Point: 214.2°C
• Appearance: /
• Density: 1.51g/cm³
• Vapor Pressure: 1.29E-07mmHg at 25°C
• Refractive Index: 1.718
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.96±0.10(Predicted)
• CAS DataBase Reference: 9-benzyl-2,6-dichloro-9H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 9-benzyl-2,6-dichloro-9H-purine(79064-26-9)
• EPA Substance Registry System: 9-benzyl-2,6-dichloro-9H-purine(79064-26-9)

Safety Data

• Hazardous Substances Data: 79064-26-9(Hazardous Substances Data)

Usage

General Description

9-benzyl-2,6-dichloro-9H-purine is a chemical compound with the molecular formula C16H11Cl2N5. It is a purine derivative with two chlorine atoms and a benzyl group attached to the purine ring. 9-benzyl-2,6-dichloro-9H-purine is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has potential applications in drug development, particularly in the field of anti-cancer and anti-inflammatory medications. Additionally, it may also be used as a research reagent in biochemical and pharmacological studies. The compound's structure and properties make it a valuable building block for the creation of novel chemical entities with potential therapeutic and agricultural benefits.

InChI:InChI=1/C12H8Cl2N4/c13-10-9-11(17-12(14)16-10)18(7-15-9)6-8-4-2-1-3-5-8/h1-5,7H,6H2

Upstream product

• 100-39-0 benzyl bromide 
• 5451-40-1 2,6 dichloropurine 
• 100-51-6 benzyl alcohol 
• 100-44-7 benzyl chloride 
• 5451-40-1 2,6-dichloropurine 
• 7285-11-2 chloroform methanol 
• 1073366-16-1 2,6-dichloropurine hydrochloride 
• 108-88-3 toluene 
• 5451-40-1 2,6-dichloro-7H-purine 

Downstream Products

• 125802-49-5 (9-Benzyl-2-chloro-9H-purin-6-yl)-p-tolyl-amine 
• 125802-51-9 N-(9-Benzyl-2-chloro-9H-purin-6-yl)-N',N'-dimethyl-benzene-1,4-diamine 
• 125802-60-0 3-(9-Benzyl-2-chloro-9H-purin-6-ylamino)-benzoic acid ethyl ester 
• 125802-62-2 (9-Benzyl-2-chloro-9H-purin-6-yl)-(3-fluoro-phenyl)-amine 
• 125802-44-0 (9-Benzyl-2-chloro-9H-purin-6-yl)-(4-butyl-phenyl)-amine 
• 125802-59-7 (9-Benzyl-2-chloro-9H-purin-6-yl)-(3-isopropoxy-phenyl)-amine 
• 125827-87-4 9-benzyl-6-(4-butoxyanilino)-2-chloro-9H-purine 
• 125802-65-5 (9-Benzyl-2-chloro-9H-purin-6-yl)-(3-methanesulfonyl-phenyl)-amine 
• 125802-47-3 (9-Benzyl-2-chloro-9H-purin-6-yl)-(4-isopropoxy-phenyl)-amine 
• 125802-57-5 9-benzyl-6-(3-butoxyanilino)-2-chloro-9H-purine 
• 125802-53-1 4-(9-Benzyl-2-chloro-9H-purin-6-ylamino)-benzonitrile 
• 125802-48-4 (9-Benzyl-2-chloro-9H-purin-6-yl)-(4-methylsulfanyl-phenyl)-amine 
• 125802-45-1 (9-Benzyl-2-chloro-9H-purin-6-yl)-(4-trifluoromethyl-phenyl)-amine 
• 115204-53-0 (9-Benzyl-2-chloro-9H-purin-6-yl)-dimethyl-amine 

Relevant articles and documents

Regioselective alkylation reaction of purines under microwave irradiation

The alkylation of purines which is generally carried out after anion formation by treatment with a base and alkyl halide is complicated and in the best cases, mixtures of N-alkylated compounds are obtained. Purine derivatives can be acquired from alkylati

HETEROCYCLIC NITROGEN-CONTAINING PURINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION

The invention relates to heterocyclic nitrogen-containing purine derivatives, their use in the medicinal applications and compositions containing these derivatives. New generation of compounds possess selective antineurodegenerative properties on neuronal cells and tissues and can be particularly used in the treatment and prophylaxis of neurodegenerative disease, particularly in the treatment and prophylaxis of Parkinson's disease.

Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl- N6-(4-morpholin-4-ylmethyl-phenyl)- 9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations

FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3. We present novel 2,6,9-trisubstituted purine derivatives with potent FLT3 inhibitory activity. The lead compound 7d displays nanomolar activity in biochemical assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive. The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis. Additionally, a single dose of 7d in mice with subcutaneous MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect observed after administration of the reference FLT3 inhibitor quizartinib.